Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study

BACKGROUND: Angiogenesis is a hallmark of head and neck squamous cell carcinoma (HNSCC), and a mechanism of resistance to EGFR inhibition. We investigated the safety and potential activity of pazopanib, an angiogenesis inhibitor, plus cetuximab, an EGFR inhibitor, in patients with recurrent or metas...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Lancet Oncol
Huvudupphovsmän: Adkins, Douglas, Mehan, Paul, Ley, Jessica, Siegel, Marilyn J, Siegel, Barry A, Dehdashti, Farrokh, Jiang, Xuntian, Salama, Noha N, Trinkaus, Kathryn, Oppelt, Peter
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561471/
https://ncbi.nlm.nih.gov/pubmed/30001987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30350-4
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk